Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba

BACKGROUND After poliomyelitis has been eradicated, access to live polioviruses will be highly restricted and the use of oral poliovirus vaccine (OPV) will probably be discontinued. Countries using OPV must decide whether to switch to inactivated poliovirus vaccine (IPV) or stop polio vaccination. Because data on the immunogenicity of IPV in tropical developing countries are limited, we conducted a randomized, controlled trial of IPV in Cuba. METHODS The study population consisted of healthy infants born in Havana. A total of 166 infants were randomly assigned to two groups. Group A received a combination of the diphtheria-pertussis-tetanus (DPT) vaccine, the Haemophilus influenzae type b (Hib) vaccine, and IPV (DPT-Hib-IPV) at 6, 10, and 14 weeks of age. Group B, the control group, received a combination of the DPT vaccine and the Hib vaccine at 6, 10, and 14 weeks of age. Another group (group C, 100 infants), which did not undergo randomization at the same time as groups A and B, received the DPT-Hib-IPV combination at 8 and 16 weeks of age. Serum samples were collected before vaccination and at least 4 weeks after the last dose. Stool samples were obtained before and 7 days after challenge with OPV. RESULTS The seroconversion rates in group A were 94%, 83%, and 100% for types 1, 2, and 3 poliovirus, respectively. There were no seroconversions in group B. The seroconversion rates in group C were 90%, 89%, and 90% for poliovirus types 1, 2, and 3, respectively. For groups A, B, and C, the virus isolation rates after challenge with OPV were 94%, 91%, and 97%, respectively, and the mean log10 viral titers of any serotype were 3.46, 3.89, and 3.37, respectively. There was one major adverse event, an episode of hypotonia. CONCLUSIONS Vaccination with two or three doses of IPV resulted in a rate of seroconversion of at least 90%, except for seroconversion against type 2. The viral titer of OPV shed in the stool after OPV challenge was reduced in both groups receiving IPV. (ClinicalTrials.gov number, NCT00260312 [ClinicalTrials.gov].).

[1]  Y. Ghendon,et al.  Comparison of the Resistance of the Intestinal Tract to Poliomyelitis virus (Sabin's Strains) in Persons after Naturally and Experimentally Acquired Immunity. , 1961 .

[2]  T. Chin,et al.  Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. , 1962, American journal of hygiene.

[3]  A. Beale,et al.  A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine , 1966, Journal of Hygiene.

[4]  J. Cherry,et al.  Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. , 1981, Pediatrics.

[5]  T. John,et al.  Efficacy of inactivated poliovirus vaccine in India. , 1983, Bulletin of the World Health Organization.

[6]  T. John,et al.  Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. , 1985, American journal of diseases of children.

[7]  P. Tukei,et al.  Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. , 1992, Bulletin of the World Health Organization.

[8]  S. Plotkin,et al.  The place of DTP/eIPV vaccine in routine pediatric vaccination , 1994 .

[9]  N. Begg,et al.  Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. , 1994, The Pediatric infectious disease journal.

[10]  S. Plotkin,et al.  Inactivated poliovirus vaccine: past and present experience. , 1996, Vaccine.

[11]  P. M. Lago,et al.  Eradication of poliomyelitis in Cuba: a historical perspective. , 1999 .

[12]  M. Pallansch,et al.  Trial of a supplemental dose of four poliovirus vaccines. , 2000, The New England journal of medicine.

[13]  M. Pallansch,et al.  Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. , 2001, International journal of epidemiology.

[14]  M. Pallansch,et al.  Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus , 2002, Science.

[15]  D. Rousset,et al.  Recombinant Vaccine–Derived Poliovirus in Madagascar , 2003, Emerging infectious diseases.

[16]  M. Pallansch,et al.  Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. , 2003, International journal of epidemiology.

[17]  J. McCormick,et al.  Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. , 2003, Vaccine.

[18]  M. Pallansch,et al.  Circulation of Endemic Type 2 Vaccine-Derived Poliovirus in Egypt from 1983 to 1993 , 2003, Journal of Virology.

[19]  Lilly Yuen,et al.  Circulation of Type 1 Vaccine-Derived Poliovirus in the Philippines in 2001 , 2004, Journal of Virology.

[20]  R. Sutter,et al.  The role of routine polio immunization in the post-certification era. , 2004, Bulletin of the World Health Organization.

[21]  D. Heymann,et al.  OPV Cessation--the Final Step To a "Polio-Free" World , 2005, Science.

[22]  M. Pallansch,et al.  Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. , 2007, The Journal of infectious diseases.